Abstract
There have been few high-quality studies of the costs, preference-based health-related quality of life (HRQoL) and cost effectiveness of treatments for primary biliary cholangitis (PBC). We aimed to estimate the marginal effects of PBC complications and symptoms, accounting for treatment, on HRQoL and the annual cost of health care in the United Kingdom (UK). These are essential components for evaluation of cost effectiveness and this information will aid in evaluation of new treatments.
Original language | English |
---|---|
Journal | CLINICAL GASTROENTEROLOGY AND HEPATOLOGY |
DOIs | |
Publication status | Published - 17 Jun 2020 |